S

Sartorius

Bioprocess and laboratory solutions provider

Field Account Manager

Full-TimeUpdated on 10/23/2026
No salary listed
Expert
Master's
Mumbai, Maharashtra, India
In PersonFrequent travel required.
Sales & Account ManagementAccount Management

About the job

Requirements
  • A master's degree in life sciences or engineering in Biotechnology or Chemical Engineering is required; a higher level of education would be beneficial.
  • At least 8 years of field sales experience is required, with laboratory or process-based experience in Life Science preferred.
  • Hands-on knowledge and proactive use of SFDC and other customer relationship management tools are required.
  • Excellent English communication and sales negotiation skills are required.
  • The candidate must be self-motivated, energetic, results-oriented, able to work independently, and responsible.
  • Good teamwork skills and the proven ability to work with cross-functional teams are required.
  • The candidate must be willing and able to travel frequently.
  • Proven software skills, such as Microsoft Office, are required.
Responsibilities
  • Promote the organization's products and services within an assigned geographic area, product range, or key account to achieve sales and revenue targets.
  • Identify new business opportunities aligned with the organization's overall market and growth strategy.
  • Use SFDC to manage and document leads, opportunities, customer interactions, and sales activities, ensuring customer and opportunity information is up to date and accurately entered in the CRM system.
  • Analyze SFDC data for assigned customers to identify trends, generate customer insights, and track sales performance.
  • Drive newly launched products and services into the marketplace and follow up proactively on the successful implementation of sales activity.
  • Assess and analyze customer needs, generate leads, respond to customer inquiries, and suggest appropriate products and services.
  • Develop and implement account plans and request and coordinate resources in line with those plans.
  • Work closely with cross-functional teams to improve market perception and develop successful strategies to gain business from an account.
  • Coordinate and participate in marketing activities in the assigned territory.
  • Frequently assess each customer's potential and plan how to realize it as business.
  • Manage and build strong customer relationships for long-term partnership.
Desired Qualifications
  • Experience in a laboratory or process-based environment in Life Science is preferred.
  • Higher education beyond the required master's degree would be beneficial.

About the company

Sartorius provides laboratory and bioprocessing equipment and services for the biopharmaceutical industry. Its two divisions, Bioprocess Solutions and Lab Products & Services, supply systems, consumables, and analytics used in biotech drug and vaccine development and production. It differentiates itself with a long history, an integrated portfolio, global support, and acquisitions like BioOutsource to offer end-to-end solutions. Its goal is to help biopharmaceutical companies develop and manufacture biotech products more reliably and at scale.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Göttingen, Germany

Founded

1870

Get referred to Sartorius

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • H1 2026 operational sales rose 7.7%, and management reaffirmed full-year guidance.
  • May 2026 bond refinancing lowered funding pressure before the €650 million maturity.
  • ElevateBio pilot validation and September 2026 ordering support Eveo sales conversion in 2027.

What critics are saying

  • Tariff refunds and customer compensation cut 2026 revenue by up to €35 million.
  • Lab Products grew only 5.3% operationally in H1 2026, lagging Bioprocess Solutions.
  • Delayed advanced-therapy orders from two customers shift revenue into 2027, hurting execution confidence.

What makes Sartorius unique

  • Eveo launches March 16, 2026, integrating cell therapy manufacturing and QC in one system.
  • Bioprocess Solutions dominates with high-recurring consumables and switching costs across biologics manufacturing.
  • Stedim Biotech integration gives Sartorius tighter control over single-use bioprocessing and global customer relationships.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Flexible Work Hours
  • Wellness Program
  • Professional Development Budget

Company News

Yahoo Finance
Oct 23rd, 2026
Sartorius Stedim Biotech nine-month sales up 7.8% to $2.5B, full-year guidance confirmed

Sartorius Stedim Biotech reported nine-month sales growth of 7.8% in constant currencies, or 6.5% after tariff-related customer compensation. Sales reached €2.29 billion, driven by strong consumables and a recovering equipment business. Underlying EBITDA rose 4.8% to €716 million, with a margin of 31.3%. Underlying net profit climbed 9.4% to €350 million, and free cash flow jumped 58.5% to €264 million. Net debt stood at €2.14 billion, or 2.26 times underlying EBITDA. Americas growth lagged at 3.9% including tariff compensation, hurt by project delays in Advanced Therapies. The company confirmed full-year guidance: operational sales growth near the midpoint of 6% to 10% and an underlying EBITDA margin slightly above 31%.

Yahoo Finance
Jul 23rd, 2026
Sartorius reports 7.7% sales growth as bioprocess equipment stabilises

Sartorius reported solid first-half results, with constant-currency sales up 7.7% and underlying EBITDA rising 3.9% as margins improved to 30.3%. Management confirmed full-year guidance. Bioprocess Solutions led performance, growing 8.3% in constant currencies. Consumables drove growth, whilst equipment stabilised slightly. Chief executive Michael Grosse said demand for biologics remains robust, particularly in monoclonal antibody manufacturing. However, advanced-therapy orders from two customers were delayed and could shift revenue into 2027. Tariff refunds and accounting effects distorted reported results but did not change underlying business trends. The company booked €26 million in customer compensation related to tariffs. Operating cash flow and free cash flow both improved sharply in the first half.

AD HOC NEWS
May 15th, 2026
Sartorius completes full takeover of Stedim Biotech, delisting bioprocessing unit from Euronext Paris

Sartorius Stedim Biotech is set to be delisted from Euronext Paris following a squeeze-out by majority shareholder Sartorius Group. The voluntary tender offer and subsequent acquisition process, which began in early 2024, will transition the company from a separately traded stock into a fully integrated part of Sartorius Group. Headquartered in Aubagne, France, Sartorius Stedim Biotech develops bioprocessing equipment and single-use technologies for biopharmaceutical manufacturing. Its products include bioreactors, filtration systems and process automation tools used by pharmaceutical and biotech companies globally. North America represents a key market, with many US-based biopharma firms using its technologies. The company experienced normalised growth following pandemic-era demand surges, with customers working through elevated inventories accumulated during vaccine production. Despite short-term headwinds, long-term demand drivers remain supported by expanding biologics and advanced therapy pipelines.

wallstreet:online AG
May 6th, 2026
Sartorius completes $560M bond placement with 3.75% coupon to refinance existing debt

Sartorius has completed a €500 million bond placement via its Dutch subsidiary Sartorius Finance B.V. The five-year bond, targeted at institutional investors, was more than four times oversubscribed and carries a 3.75% annual coupon. The life science group will use the proceeds for general corporate purposes, including refinancing existing debt. This includes the redemption of a €650 million bond with a 4.25% interest rate due in autumn 2026. Sartorius has applied for admission to trading on the Euro MTF market of the Luxembourg Stock Exchange. Chief financial officer Florian Funck said the successful issuance strengthens the company's balanced debt maturity profile and long-term financing position, whilst demonstrating investor confidence in Sartorius' strategic direction.

Sartorius
May 6th, 2026
Sartorius completes placement of bond with a volume of 500 million euros

May 6, 2026 – Sartorius has successfully issued a bond with a volume of 500 million euros via its Dutch subsidiary Sartorius Finance B.V.. The issue was targeted at institutional investors and met with strong demand, being more than 4 times oversubscribed.